ADC Therapeutics SA

ADCT · NYSE

ADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.

Follow Add to Watchlist Ask Question

NYSE ADCT Coverage Bootstrap Biotechnology Oncology Antibody Drug Conjugates

Latest ReportMay 14, 2026ADC Therapeutics: the lymphoma readout trying to beat the royalty wallView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

OncologyADCT

Clear tags

MatchAny tag All tags

Latest Thesis

ADC Therapeutics: the lymphoma readout trying to beat the royalty wall

May 14, 2026Research reportSlides available

Read report Open slides Discussion (0)

ADC Therapeutics SATherapeutics: the lymphoma readout trying to beat the royalty waMay 14, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->